Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study

This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

开始日期2022-06-20

申办/合作机构

Daewoong Pharmaceutical Co., Ltd.

NCT05259020 / Unknown status临床1期

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over, Clinical Trial to Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers.

To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.

开始日期2022-02-22

申办/合作机构

Ildong Pharmaceutical Co., Ltd.

NCT05155137 / Recruiting临床3期IIT

Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care

This study is a phase III Randomized Clinical Trial, prospective, placebo controlled of 12,268 subjects with low to moderate risk of stroke followed by 3 years in 60 Primary Health Care Units in Brazil. The units will be randomized (clusters) to use or not the approach of community health workers with the Stroke Riskometer. After, patients will be randomized to receive the polypill (valsartan 80 mg, amlodipine 5 mg and rosuvastatin 10 mg) or placebo (dose adjustment of amlodipine 2,5 for patients with adverse events). The purpose is to test whether a polypill alone or in combination with lifestyle modification will reduce the incidence of stroke and cognitive impairment in this population.

开始日期2021-12-20

申办/合作机构

Hospital Moinhos de Vento

[+1]

100 项与 HMG-CoA reductase x VDCCs x AT1R 相关的临床结果

登录后查看更多信息

100 项与 HMG-CoA reductase x VDCCs x AT1R 相关的转化医学

登录后查看更多信息

0 项与 HMG-CoA reductase x VDCCs x AT1R 相关的专利（医药）

登录后查看更多信息

项与 HMG-CoA reductase x VDCCs x AT1R 相关的文献（医药）

2002-06-01·Journal of Hypertension2区 · 医学

A gene expression analysis in rat kidney following high and low salt intake

2区 · 医学

Article

作者: Dechend, Ralf ; Luft, Friedrich C. ; Gorzelniak, Kerstin ; Maass, Philipp G. ; Monti, Jan ; Sharma, Arya M. ; Barta, Peter ; Hubner, Norbert ; Muller, Dominik N.

BACKGROUNDThe effects of salt intake on renal regulation have been investigated for decades. To find new pathways and to demonstrate the utility of oligonucleotide expression arrays, we studied whole kidneys.METHODSEight Sprague-Dawley rats were divided into two groups. One group received a 6% salt (by weight) diet, while the other group received a 0.3%, otherwise identical, salt diet for 7 days. The rats were sacrificed after 7 days and the left kidney was subjected to RNA extraction. Oligonucleotide expression arrays (Affymetrix) were used to determine downregulation and upregulation, comparing high with low salt intake. Four rats from each group were studied separately.RESULTSThe experiments were reproducible. Thirty genes were downregulated with the high-salt diet, while 35 genes were upregulated. The renin gene, beta-2 glycoprotein-1, retinol binding protein, annexin VI, and the PTP2C protein tyrosine phosphatase were among the downregulated genes. The angiotensin II receptor type 1B receptor, HMG-CoA reductase, B7 antigen, and the rat calcium channel beta subunit III were among the upregulated genes. Differentially regulated were the p55 subunit (upregulated) and the p50 subunit (downregulated) of the phosphatidyl inositol 3-kinase enzyme complex. We verified our results by selecting a high-salt downregulated gene (renin) and an upregulated gene (B7 antigen) and subjecting these genes to real-time polymerase chain reaction. The results were consistent.CONCLUSIONOligonucleotide expression arrays can detect novel genes encoding for proteins not generally associated with responses to varied salt intake. Experiments of this nature have substantial limitations and require detailed verification. However, overall, the utility is promising.

项与 HMG-CoA reductase x VDCCs x AT1R 相关的新闻（医药）

2023-05-28

·医药地理

2022年获批进口药品分析（心血管系统用药、神经系统用药）

本文数据来自于CPM新药研发监测数据库（cpm.pharmadl.com）。心血管系统用药2022年NMPA批准的进口心血管系统用药，共计71个（按照注册证号分类），获批品种数量前五的几家企业分别为拜耳（12个）、赛诺菲（8个）、勃林格殷格翰（7个）、Kyowa Kirin（6个）、Organon Pharma（6个）；涉及靶点排名前三的是AGTR1（20个）、CACNA1C（14个）、Hmgcr（14个）。在政策相关度方面，2022年获批的进口心血管系统用药中，2022国家医保目录品种共有67个，没有带量采购招标品种。神经系统用药2022年NMPA批准的进口神经系统用药，共计55个（按照注册证号分类），获批品种前三的企业分别是Napp Pharmaceuticals（8个）、Dr Reddy's Laboratories（6个）、Mundipharma Research（6个）；涉及靶点排名前三的是Nav1.1（9个）、ACHE（7个）、OPRK1（6个）。在政策相关度方面，2022年获批的进口神经系统用药中，2022国家医保目录品种共有49个，没有带量采购招标品种。年度发布2023年《全球药研新动态》《中国医院市场用药格局》（2023版）2023年《数图药讯》权威发布2021年度中国医药工业百强榜单解读中国仿制药发展报告（2022版）医药行业专项报告中国医药中间体和原料药行业调研报告中国非甾体抗炎类原料药市场调研报告中国祛痰类原料药市场调研报告中国钙拮抗剂类原料药市场调研报告中国血管紧张素Ⅱ受体拮抗剂类原料药市场调研报告中国口服血糖调节类原料药市场调研报告中国中枢兴奋类原料药市场调研报告中国抗痛风类原料药市场调研报告中国脑血管病类原料药市场调研报告END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

带量采购